GUANGZHOU, China, Feb. 27 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME; "China Medicine" or "the Company"), a leading distributor and developer of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines ("TCM"), nutritional and dietary supplements, medical devices, and medical formulations in the People's Republic of China ("PRC"), through its wholly-owned U.S subsidiary, Konzern U.S Holding Corporation, announced today that it will participate in the 2009 Natural Products Expo West tradeshow, where it will showcase its weight loss product called 'BeThin.'
The tradeshow will be held from March 5th to March 8th at the Anaheim Convention Center in California. It is the largest natural and organic products trade show in the world, and is expected to attract more than 50,000 attendees and feature more than 3,000 exhibits this year.
China Medicine's proprietary weight loss product, BeThin, is a food supplement that is designed to promote and adjust fat metabolism, reduce the storage of fat in the body, and prolong endurance during physical exercise. In addition, the product is free from caffeine and ephedrine. The Company has filed and obtained the necessary documentation to launch the new product in the United States.
"We are looking forward to participating in the Natural Products Expo in the U.S. for a second time," said Senshan Yang, Chairman and CEO of China Medicine. "Last October, we participated in the Natural Products Expo East tradeshow in Boston with favorable results, and as a result we are now cooperating with a supermarket chain to access the market for supplements in New York. We are confident that frequent exposure to BeThin at trade shows will lead to more market visibility and positive results."
The Company will be exhibiting its product in booth #1268. For more information on the tradeshow, please click http://www.expowest.com .
About China Medicine Corporation
China Medicine Corporation is a leading pharmaceutical company which discovers and develops medical formulations and distributes over 2,200 pharmaceutical products in China including prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements. The Company distributes the products to wholesale distributors in 28 provinces, more than 300 hospitals, 500 medicine companies, and 1,788 drug stores throughout China. The Company actively develops a number of proprietary products for many uses including oncology, high blood pressure and the removal of toxins from food and animal feed. For more information visit the Company's website at http://www.chinamedicinecorp.com .
Cautionary Statement
This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
For more information, please contact:
Company Contact:
Ms. Huizhen Yu
Chief Financial Officer
China Medicine Corporation
Tel: +86-20-8739 1718
Email: konzern08@163.com
Investor Relations Contact:
Mr. Crocker Coulson
President
CCG Investor Relations
Tel: +1-646-213-1915 (NY Office)
Email: crocker.coulson@ccgir.com
